retatrutide phase 2 results 2024 2025 The Effect of on Kidney Parameters in Participants With Type Diabetes Mellitus and/or Obesity Phase 2 trial results demonstrate

Retatrutide is being studied as a triple agonist, while tirzepatide is an approved dual agonist for certain indications

Compounded semaglutide is not FDA approved and may come with risks like dosing errors and contamination

International travel poses unique challenges

This blend targets researchers studying the interaction between triple agonist signaling and amylin receptor agonism

A Clear Verdict Based On Current Evidence To date, there are no peer-reviewed human trials demonstrating that consumer GLP-1 patches activate GLP-1 receptors, support clinically meaningful appetite changes, or influence blood sugar through the same mechanisms as prescription medications

Studies show that GLP-1 receptor agonists, drugs that mimic GLP-1, have been shown to help people with type 2 diabetes (T2D) and obesity lose weight and control their blood sugar [2]